BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 22172461)

  • 21. A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.
    Voutsadakis IA; Cairoli A
    Leuk Lymphoma; 2012 May; 53(5):779-88. PubMed ID: 21955212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
    Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
    Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
    [No Abstract]   [Full Text] [Related]  

  • 23. Myelodysplastic syndromes with 5q deletion: pathophysiology and role of lenalidomide.
    Gaballa MR; Besa EC
    Ann Hematol; 2014 May; 93(5):723-33. PubMed ID: 24627193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
    Kelaidi C; Park S; Brechignac S; Mannone L; Vey N; Dombret H; Aljassem L; Stamatoullas A; Adès L; Giraudier S; de Botton S; Raynaud S; Lepelley P; Picard F; Leroux G; Daniel MT; Bouscary D; Dreyfus F; Fenaux P;
    Leuk Res; 2008 Jul; 32(7):1049-53. PubMed ID: 18191202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
    Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
    Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
    Giagounidis AA; Haase S; Heinsch M; Göhring G; Schlegelberger B; Aul C
    Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
    Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
    Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
    [No Abstract]   [Full Text] [Related]  

  • 28. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
    Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
    Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
    [No Abstract]   [Full Text] [Related]  

  • 29. Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q).
    Chen C; Bowen DT; Giagounidis AA; Schlegelberger B; Haase S; Wright EG
    Leukemia; 2010 Nov; 24(11):1875-84. PubMed ID: 20739954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Van-den Berghe's 5q- syndrome in 2008.
    Mohamedali A; Mufti GJ
    Br J Haematol; 2009 Jan; 144(2):157-68. PubMed ID: 19016715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
    Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
    Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion.
    Sánchez-García J; Del Cañizo C; Lorenzo I; Nomdedeu B; Luño E; de Paz R; Xicoy B; Valcárcel D; Brunet S; Marco-Betes V; García-Pintos M; Osorio S; Tormo M; Bailén A; Cerveró C; Ramos F; Diez-Campelo M; Such E; Arrizabalaga B; Azaceta G; Bargay J; Arilla MJ; Falantes J; Serrano-López J; Sanz GF;
    Br J Haematol; 2014 Jul; 166(2):189-201. PubMed ID: 24716538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
    Le Bras F; Sebert M; Kelaidi C; Lamy T; Dreyfus F; Delaunay J; Banos A; Blanc M; Vey N; Schmidt A; Visanica S; Eclache V; Turlure P; Beyne-Rauzy O; Guerci A; Delmer A; de Botton S; Rea D; Fenaux P; Adès L
    Leuk Res; 2011 Nov; 35(11):1444-8. PubMed ID: 21715006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.
    Mallo M; Del Rey M; Ibáñez M; Calasanz MJ; Arenillas L; Larráyoz MJ; Pedro C; Jerez A; Maciejewski J; Costa D; Nomdedeu M; Diez-Campelo M; Lumbreras E; González-Martínez T; Marugán I; Such E; Cervera J; Cigudosa JC; Alvarez S; Florensa L; Hernández JM; Solé F
    Br J Haematol; 2013 Jul; 162(1):74-86. PubMed ID: 23614682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of lenalidomide in the treatment of patients with chromosome 5q deletion and other myelodysplastic syndromes.
    Melchert M; Kale V; List A
    Curr Opin Hematol; 2007 Mar; 14(2):123-9. PubMed ID: 17255789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.
    Eclache V; Da Rocha A; Le Roux G; Fenaux P
    Haematologica; 2008 Feb; 93(2):315-6. PubMed ID: 18245660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
    Göhring G; Lange K; Hofmann W; Nielsen KV; Hellström-Lindberg E; Roy L; Morgan M; Kreipe H; Büsche G; Giagounidis A; Schlegelberger B
    Leukemia; 2012 Feb; 26(2):356-8. PubMed ID: 21799512
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
    Ximeri M; Galanopoulos A; Klaus M; Parcharidou A; Giannikou K; Psyllaki M; Symeonidis A; Pappa V; Kartasis Z; Liapi D; Hatzimichael E; Kokoris S; Korkolopoulou P; Sambani C; Pontikoglou C; Papadaki HA;
    Haematologica; 2010 Mar; 95(3):406-14. PubMed ID: 19773257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide in del 5q MDS: responses and side effects revisited.
    Tiu RV; Sekeres MA
    Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
    [No Abstract]   [Full Text] [Related]  

  • 40. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
    Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
    Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.